Prediction of Acute-phase Complications in Patients with Infectious Endocarditis.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Aug 2019
Historique:
pubmed: 24 5 2019
medline: 18 12 2019
entrez: 24 5 2019
Statut: ppublish

Résumé

Objective Embolic events are frequent and life-threatening complications of infective endocarditis (IE). Recently, an embolic risk assessment at admission, based on the Embolic Risk (ER) French Calculator, was designed to predict the development of symptomatic emboli associated with IE. This study aimed to validate the ER French Calculator for the prediction of in-hospital events, including embolic events. Methods We retrospectively analyzed the clinical features of 52 consecutive patients with left-sided IE to identify possible predictors of in-hospital events within 30 days of admission. Results New embolic events were seen in 15 patients (29%), cardiac surgery was performed in 22 patients (42%), and 1 patient (2%) died within 30 days of admission. A composite endpoint of embolic complications, cardiac surgery, or death was observed in 28 patients (54%). The cumulative incidence of new embolic events was significantly higher in the high-risk group identified by the ER French Calculator than in the low-risk group (log-rank test; p=0.0004). The incidence of the composite endpoint was higher in the high-risk group than in the low-risk group (log-rank test; p<0.0001). A multivariate Cox proportional hazards model indicated that the high-risk designation on the ER French Calculator predicted embolic events (p=0.0410) and composite events (p=0.0371) independently of other candidate predictors. Conclusion The ER French Calculator may be a useful tool for predicting new in-hospital embolic events and other unfavorable in-hospital events in patients with IE.

Identifiants

pubmed: 31118367
doi: 10.2169/internalmedicine.1813-18
pmc: PMC6746645
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2323-2331

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

J Am Coll Cardiol. 1999 Apr;33(5):1365-71
pubmed: 10193740
J Am Coll Cardiol. 2002 May 1;39(9):1489-95
pubmed: 11985912
JAMA. 2003 Dec 24;290(24):3207-14
pubmed: 14693873
Clin Microbiol Infect. 2004 Jan;10(1):46-53
pubmed: 14706086
Circulation. 2005 Jul 5;112(1):69-75
pubmed: 15983252
Int J Cardiol. 2006 Jun 28;110(3):334-9
pubmed: 16213607
Heart. 2006 Jul;92(7):879-85
pubmed: 16216860
Am Heart J. 2005 Nov;150(5):1086-91
pubmed: 16291003
Eur Heart J. 2007 May;28(9):1155-61
pubmed: 17363448
Am Heart J. 2007 Dec;154(6):1086-94
pubmed: 18035080
Clin Infect Dis. 2008 Jul 1;47(1):23-30
pubmed: 18491965
Eur Heart J. 2011 Aug;32(16):2003-15
pubmed: 19208650
Circulation. 2009 Aug 18;120(7):585-91
pubmed: 19652096
Circulation. 2010 Mar 2;121(8):1005-13
pubmed: 20159831
Ann Intern Med. 2010 Apr 20;152(8):497-504, W175
pubmed: 20404380
Circulation. 2010 Sep 14;122(11 Suppl):S17-22
pubmed: 20837909
Lancet. 2012 Mar 10;379(9819):965-975
pubmed: 22317840
N Engl J Med. 2012 Jun 28;366(26):2466-73
pubmed: 22738096
Interact Cardiovasc Thorac Surg. 2012 Dec;15(6):1052-6
pubmed: 22962320
J Am Coll Cardiol. 2013 Oct 8;62(15):1384-92
pubmed: 23906859
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
Circulation. 2015 Oct 13;132(15):1435-86
pubmed: 26373316
Cardiol Res. 2016 Aug;7(4):130-139
pubmed: 28197281
J Cardiol. 2017 Dec;70(6):607-614
pubmed: 28506640

Auteurs

Fumiya Saito (F)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Shigeru Toyoda (S)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Takuo Arikawa (T)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Shu Inami (S)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Ryo Watanabe (R)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Syotaro Obi (S)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Masashi Sakuma (M)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Tomoaki Kanaya (T)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Shichiro Abe (S)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Toshiaki Nakajima (T)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Teruo Inoue (T)

Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH